AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Hereditary Spastic Paraplegia

Recent research efforts aimed at curing Hereditary Spastic Paraplegia.

Last updated

Hereditary Spastic Paraplegia

Overview

Hereditary spastic paraplegia (HSP) is a large group of inherited neurological disorders in which damage to the longest nerve pathways controlling leg movement causes progressive stiffness, weakness, brisk reflexes, and difficulty walking. “Pure” HSP mainly affects the legs and bladder function, while “complex” HSP can also involve developmental delay, intellectual disability, seizures, neuropathy, vision problems, ataxia, or other neurological features. Age of onset and prognosis vary greatly by genetic subtype: many pure forms progress slowly and do not shorten lifespan, whereas some childhood-onset complex forms are severe and neurodevelopmental as well as neurodegenerative. GeneReviews overview Clinical and genetic spectrum

There is currently no approved treatment that reverses the underlying nerve degeneration across HSP. Standard care is individualized, multidisciplinary symptom management: physiotherapy and stretching, mobility aids and orthotics when needed, medicines or injections to reduce spasticity, and treatment for bladder, pain, orthopedic, speech, swallowing, or cognitive issues according to the subtype. GeneReviews overview

Scope of Recent Research (2020–present)

Research since 2020 has become more biologically precise, moving from broadly treating spasticity toward correcting specific genetic and cellular defects. The field remains small and fragmented because HSP encompasses more than 80 genetic disorders, but the AP4M1-related subtype SPG50 has become a landmark: it has progressed from patient-cell and animal studies to a single-patient trial and then to a recruiting pivotal phase 3 gene-therapy study. This is meaningful progress toward a potential disease-modifying treatment for one subtype, not evidence of a near-term universal cure for all HSP. HSP genomic initiative MELPIDA phase 3 trial

Major Breakthroughs and Emerging Therapies

The leading curative strategy is gene replacement for SPG50, a severe childhood-onset HSP caused by loss-of-function variants in AP4M1. Researchers developed an adeno-associated virus type 9 (AAV9) vector carrying a functioning AP4M1 gene and administer it into cerebrospinal fluid by intrathecal injection, aiming to reach neurons throughout the central nervous system. In patient-derived cells and animal models, AAV9/AP4M1 restored AP-4 complex function and produced favorable preclinical safety and efficacy findings, providing the rationale for human studies. AAV9/AP4M1 preclinical study

In 2024, investigators reported the first individualized phase 1 AAV gene-replacement treatment for SPG50 in a four-year-old child. The treatment was well tolerated through 12 months, with no serious adverse events reported; the child had transient neutropenia and Clostridioides difficile gastroenteritis that resolved. Measures of development and motor function suggested stabilization relative to the expected disease course, but this was an uncontrolled study in one person and therefore cannot establish efficacy or prove a cure. Single-patient SPG50 phase 1 trial

Other approaches seek to rescue shared mechanisms of axonal degeneration rather than replace one gene. In SPG11 and SPG48 patient-derived cortical neurons, the experimental peptide P110 inhibited excessive mitochondrial fission, improved mitochondrial movement and energy production, reduced neurofilament abnormalities, and lowered release of phospho-neurofilament heavy chain, a potential marker of axonal injury. These results are promising preclinical evidence, but P110 has not yet been established as an HSP treatment in people. Mitochondrial-fission inhibition study

For SPG4, the most common autosomal-dominant pure HSP, researchers have used gene-edited, patient-relevant cortical organoids and mouse models to identify excessive HDAC6 activity and loss of microtubule acetylation as potentially treatable disease mechanisms. The HDAC6 inhibitor tubastatin A restored microtubule acetylation and reduced axonal degeneration in organoids, while also improving corticospinal-tract integrity and gait in transgenic mice. This remains laboratory-stage work, but it illustrates a potential small-molecule alternative for disorders in which simply adding a gene may not be sufficient or practical. SPG4 organoid and HDAC6 study

RNA-based therapies are also being explored at an early stage, particularly for SPG4. The Spastic Paraplegia Foundation has supported projects developing antisense oligonucleotides—short synthetic nucleic-acid medicines that can alter RNA processing—as well as SPG4 gene-therapy and antibody projects. These programs show growing interest in mutation-specific treatment, but they should not be interpreted as clinical therapies until peer-reviewed preclinical results and human safety data are available. Spastic Paraplegia Foundation grants

Clinical Trials and Experimental Approaches

The most consequential active interventional study is the recruiting phase 3 MELPIDA trial for SPG50, sponsored by Elpida Therapeutics SPC with collaborators including the University of Texas Southwestern Medical Center and Hospital Sant Joan de Déu. MELPIDA is a one-time intrathecal AAV9/AP4M1 gene-replacement therapy. The trial began on April 1, 2026, plans to enroll 24 participants, and compares treated participants with prospectively matched concurrent controls over 156 weeks; primary and secondary measures include major gross-motor milestones, cognition, spasticity, and the Spastic Paraplegia Rating Scale. No trial results had been posted in the registry at the latest update. MELPIDA phase 3 trial

The phase 3 program follows the published single-patient phase 1 study at The Hospital for Sick Children in Toronto, which was supported by SickKids, the CureSPG50 Foundation, and collaborators in Canada and the United States. Its preliminary safety and stabilization findings enabled broader development, but confirmation now depends on the controlled phase 3 study. Single-patient SPG50 phase 1 trial

Observational studies are also essential because they establish the natural history and outcome measures needed to test therapies in very rare diseases. Boston Children’s Hospital’s HSP sequencing initiative is recruiting individuals under age 30 with suspected HSP for genetic and phenotype studies, while the AP-4-HSP registry and natural-history study is collecting longitudinal clinical data, imaging, blood, fibroblasts, and induced pluripotent stem cells. HSP genomic initiative AP-4-HSP natural-history registry

Methodologies and Scientific Approaches

Modern HSP research combines deep genetic diagnosis with patient-specific disease models. Investigators create induced pluripotent stem cells from patient blood or skin cells, differentiate them into corticospinal neurons—the long-projecting brain cells particularly vulnerable in HSP—and compare them with gene-corrected or engineered control cells. These systems permit direct measurement of axon length, mitochondrial transport, energy production, neurofilament accumulation, autophagy, and cell survival, while cortical organoids provide a more complex human tissue model for testing drug responses. Mitochondrial-fission inhibition study SPG4 organoid and HDAC6 study

For gene therapy, teams test AAV vector distribution, transgene expression, dose, immune effects, and functional outcomes in patient cells and animal models before intrathecal delivery in people. Clinical programs increasingly pair these approaches with standardized motor scales, developmental testing, imaging, digital or structured gait measures, and longitudinal registries so that an individual’s treatment response can be interpreted against the expected course of their specific subtype. AAV9/AP4M1 preclinical study AP-4-HSP natural-history registry

Leading Institutions and Funding

The SPG50 gene-therapy effort has brought together The Hospital for Sick Children and University of Toronto, the University of Texas Southwestern Medical Center, Boston Children’s Hospital, the U.S. National Institutes of Health, the CureSPG50 Foundation, Viralgen, and Elpida Therapeutics. The preclinical AAV9/AP4M1 work was supported by the CureSPG50 Foundation and the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, while the first clinical treatment was supported through philanthropic funding to SickKids and CureSPG50 Foundation support for manufacturing and clinical-trial preparation. NIH SPG50 research update Single-patient SPG50 phase 1 trial

Patient foundations remain especially influential in HSP because commercial incentives are weak for ultra-rare subtypes. The Spastic Paraplegia Foundation has funded projects on SPG11, SPG4 antisense and gene-therapy approaches, mitochondrial biology, imaging biomarkers, and pharmacological screening. In a January 2025 public funding proposal, the California Institute for Regenerative Medicine listed a request of $14.9 million for an AAV9/AP4M1 SPG50 pivotal trial, illustrating the unusually high cost of moving a bespoke rare-disease gene therapy into late-stage development. Spastic Paraplegia Foundation grants CIRM SPG50 funding proposal

Strengths, Limitations, and Challenges

A major strength of the field is that several HSP subtypes have clearly defined single-gene causes, enabling rational gene replacement or mutation-targeted treatments. SPG50 demonstrates that a family-led and academic collaboration can develop a therapy rapidly enough to reach human testing, and the ongoing phase 3 study has clinically meaningful motor, cognitive, and spasticity endpoints rather than relying only on laboratory biomarkers. Single-patient SPG50 phase 1 trial MELPIDA phase 3 trial

The central limitations are genetic diversity, very small patient populations, and uncertainty about the point at which damaged long axons can still be rescued. A treatment that works for recessive AP4M1 deficiency may not work for dominant SPAST disease or complex metabolic and lysosomal forms of HSP. The initial SPG50 clinical evidence involved one child and suggested stabilization rather than restoration of lost function; the pivotal trial is open-label and small, so durable benefit, safety, equitable access, manufacturing capacity, and price will remain major questions even if it succeeds. Clinical and genetic spectrum Single-patient SPG50 phase 1 trial MELPIDA phase 3 trial

Outlook and Future Directions

HSP is not close to a single universal cure, but SPG50 has moved further toward disease modification than any other HSP subtype, with a recruiting phase 3 AAV gene-replacement trial underway as of August 8, 2026. The critical milestones to watch are phase 3 MELPIDA safety and motor-development results, longer-term durability after one-time intrathecal treatment, validation of biomarkers and natural-history controls, and translation of organoid and neuron findings—such as HDAC6 inhibition and mitochondrial rescue—into reproducible animal and then human studies. The broader route to curing HSP will probably be a portfolio of subtype-specific gene, RNA, metabolic, and small-molecule therapies rather than one treatment for all forms. MELPIDA phase 3 trial SPG4 organoid and HDAC6 study Mitochondrial-fission inhibition study

References

Don't see your disease? Request a report